Actively Recruiting
Examination of Alzheimer's Disease Biomarkers in Tears and Dry Blood Spots
Led by Danish Dementia Research Centre · Updated on 2024-08-22
600
Participants Needed
1
Research Sites
152 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating whether Alzheimer's disease biomarkers can be detected in tear fluid and dried blood spots from patients with Alzheimer's disease, other dementia types, and control participants without neurological disease. This observational study focuses on people undergoing evaluation for neurodegenerative diseases at a memory clinic, aiming to compare biological markers across these groups to improve understanding of Alzheimer's and related dementias. On the day participants have a lumbar puncture as part of their clinical evaluation, samples of tear fluid and dried blood spots will be collected. Tear fluid is gathered using Shirmer's test, while dried blood spots are made from a small finger prick onto filter paper. A sub-study invites consenting participants to repeat the dried blood spot test at home one week later, submitting samples at their next clinic visit. These samples, along with blood and cerebrospinal fluid, will be examined for Alzheimer's disease-related pathology. Participants will provide tear fluid, dried blood spots, blood, and cerebrospinal fluid samples during their clinical visits. Researchers will analyze these samples to identify Alzheimer's biomarkers over a two-year period. The study involves patients diagnosed with Alzheimer's disease, other dementias, and control individuals without neurological disease. Safety and fitness for participation are assessed, and the total study duration depends on clinical schedules and sample collections.
CONDITIONS
Brief Title
Blood And Tears in Alzheimer's Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Lumbar puncture with cerebrospinal fluid available for analysis
- Diagnosis of Alzheimer's disease, Dementia with Lewy Bodies, Frontotemporal dementia, vascular dementia, or Normal pressure hydrocephalus
- Of legal age
- Controls must have lumbar puncture with cerebrospinal fluid available and no neurological disease
- Controls must be of legal age
You will not qualify if you...
- No lumbar puncture performed
- Clinically assessed as unfit to participate in the project
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 day
Participants undergo lumbar puncture and collection of tear fluid and dried blood spots to examine Alzheimer's disease biomarkers.
1 visit (in-person)
Duration - 1 week plus time until next appointment
Participants who consent to the sub-study collect dried blood spots at home one week after the initial visit and submit samples at their next scheduled appointment.
1 home collection and 1 follow-up visit
Duration - Two years
Participants' Alzheimer's disease biomarkers in tear fluid and dried blood spots are evaluated over two years.
visit schedule depends on clinical follow-up
Trial Site Locations
Total: 1 location
1
Danish Dementia Research Centre
Copenhagen, Denmark, 2100
Actively Recruiting
Research Team
S
Steen G Hasselbalch, DMSc
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here